DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: DEFINITY

Summary for Tradename: DEFINITY

Patents:4
Applicants:1
NDAs:1
Suppliers: see list1
drug
patent expirations by year for
 DEFINITY

Pharmacology for Tradename: DEFINITY

Clinical Trials for: DEFINITY

Evaluation of Intra-operative Ultrasound Contrast Enhancement in the Evaluation of Liver Tumors
Status: Terminated Condition: Liver Tumors

3-D Transcranial Ultrasound Analysis Study
Status: Completed Condition: Cerebrovascular Accident; Intracranial Hypertension

A Prospective, Phase IV, Surveillance Registry Study to Evaluate the Safety of DEFINITY® in Clinical Practice
Status: Completed Condition: Cardiovascular Disease

A Study of Commercial DEFINITY® to Monitor the Effects of the Heart's Pulmonary Artery Pressure
Status: Completed Condition: Pulmonary Heart Disease

Breast VCEUS to Evaluate Early Response to Neoadjuvant Chemotherapy
Status: Not yet recruiting Condition: Breast Cancer

Estimation of Pulmonary Vascular Resistance by Contrast Echocardiography
Status: Completed Condition: Pulmonary Arterial Hypertension

Definity for Ultrasound of Intraocular Tumors
Status: Recruiting Condition: Ocular Melanoma

DMP115 in Patients With an Ejection Fraction Between 25%-40% to Evaluate the Use of Contrast Echocardiography to Assess Heart Function
Status: Completed Condition: Ventricular Ejection Fraction

A Pilot Study of the Effects of Contrast Enhanced Endoscopic Ultrasound on Determining Vascular Involvement in Pancreatic Lesions
Status: Not yet recruiting Condition: Pancreatic Tumors

Effects of Nebivolol on Skeletal Muscle During Exercise in Hypertensive Patients
Status: Recruiting Condition: Hypertension

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lantheus Medcl
DEFINITY
perflutren
INJECTABLE;INTRAVENOUS021064Jul 31, 2001RXYes5,527,521<disabled>Y<disabled>
Lantheus Medcl
DEFINITY
perflutren
INJECTABLE;INTRAVENOUS021064Jul 31, 2001RXYes5,585,112<disabled>Y<disabled>
Lantheus Medcl
DEFINITY
perflutren
INJECTABLE;INTRAVENOUS021064Jul 31, 2001RXYes6,033,645<disabled><disabled>
Lantheus Medcl
DEFINITY
perflutren
INJECTABLE;INTRAVENOUS021064Jul 31, 2001RXYes8,658,205<disabled>Y<disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc